- Home
- HURA vs DTIL Comparison
HURA vs DTIL Comparison
Compare HURA & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HURA | DTIL |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.8M | 97.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HURA | DTIL |
|---|---|---|
| Price | $0.66 | $4.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | ★ $60.00 |
| AVG Volume (30 Days) | ★ 306.4K | 251.1K |
| Earning Date | 02-14-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $698,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.66 | $3.75 |
| 52 Week High | $5.27 | $8.82 |
Technical Indicators
Market Signals| Indicator | HURA | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 27.79 | 48.05 |
| Support Level | $0.68 | $3.90 |
| Resistance Level | $0.73 | $4.21 |
| Average True Range (ATR) | 0.06 | 0.29 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 9.03 | 60.54 |
Price Performance
Historical ComparisonAbout HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.